Annonce

Log ud Log ind
Log ud Log ind
Samfundsansvar

Nye data: Pfizer vaccine kun 42 % effektiv efter en tid, booster nødvendig

Morten W. Langer

fredag 13. august 2021 kl. 7:38

Uddrag fra Zerohedge:

This week, Dr. Fauci confirmed that “at some time in the future” everyone will likely need a booster shot for the Covid-19 vaccine due to “fading efficacy.”

Now, Axios reports that a new preprint study which has ‘already grabbed the attention of top Biden administration officials’ over the vaccines’ effectiveness against new variants, with Pfizer’s jab being of particular concern.

The study found the Pfizer vaccine was only 42% effective against infection in July, when the Delta variant was dominant. “If that’s not a wakeup call, I don’t know what is,” a senior Biden official told Axios.

The study, conducted by nference and the Mayo Clinic, compared the effectiveness of the Pfizer and Moderna vaccines in the Mayo Clinic Health System over time from January to July. -Axios

The overall figures suggest that the vaccines provide robust (yet lower-than advertised) immunity early on, only to sharply drop in efficacy over time.

Between January and July, Moderna’s vaccine was found to be 86% effective against infection over the study period, while Pfizer’s was 76%. As far as hospitalization, Moderna’s vaccine was 92% effective, while Pfizer’s was 85%.

Bringing the averages down, of course, was the sharp drop in efficacy observed in July with Moderna proving just 72% effective against infection and Pfizer clocking in at 42%.

In other states such as Florida, the risk of infection in July among those who had taken the Moderna vaccine was around 60% lower than for people full vaccinated with Pfizer.

More via Axios:

Why it matters: Although it has yet to be peer-reviewed, the study raises serious questions about both vaccines’ long-term effectiveness, particularly Pfizer’s.

  • It’s unclear whether the results signify a reduction in effectiveness over time, a reduced effectiveness against Delta, or a combination of both.
  • “Based on the data that we have so far, it is a combination of both factors,” said Venky Soundararajan, a lead author of the study. “The Moderna vaccine is likely — very likely — more effective than the Pfizer vaccine in areas where Delta is the dominant strain, and the Pfizer vaccine appears to have a lower durability of effectiveness.”
  • He added that his team is working on a follow-up study that will try to differentiate between the durability of the two vaccines and their effectiveness against Delta.

Få dagens vigtigste
økonominyheder hver dag kl. 12

Bliv opdateret på aktiemarkedets bevægelser, skarpe indsigter
og nyeste tendenser fra Økonomisk Ugebrev – helt gratis.

Jeg giver samtykke til, at I sender mig mails med de seneste historier fra Økonomisk Ugebrev.  Lejlighedsvis må I gerne sende mig gode tilbud og information om events. Samtidig accepterer jeg ØU’s Privatlivspolitik. Du kan til enhver tid afmelde dig med et enkelt klik.

[postviewcount]

Jobannoncer

Vi søger to studentermedhjælpere til Dansk Sygeplejeråds Økonomiafdeling
Region Hovedstaden
Dansk Sygeplejeråd søger regnskabskonsulent med erfaring i regnskabsprocessen fra A-Z
Region Hovedstaden
Finance Manager
Region Syddanmark
Financial Controller
Region Nordjylland
Rigspolitiet søger en administrationschef til Bornholms Politi
Bornholms Regionskommune
Har du økonomisk og analytisk forståelse samt interesse for ledelsesbetjening? Vi søger to økonomikonsulenter til Sundheds- og Omsorgsforvaltningen
Region Hovedstade
Talstærk analytiker til analysekontor
Region Hovedstaden
Chef for Digitalisering og Økonomi
Region Sjælland
Udløber snart
Kontorchef til Center for Økonomi og Koncern i Indenrigs- og Sundhedsministeriets departement
Region Hovedstaden
Dansk Erhverv søger skattepolitisk fagchef
Regiopn Hovedstaden
Strategisk Finans Partner i Forca
Region Hovedstaden
Brænder du for klagesagsbehandling, har vi jobbet for dig
Region Hovedstaden
To medarbejdere til økonomistyring i Budgetenheden, Koncern Økonomi
Region Sjælland

Mere fra ØU Samfundsansvar

Log ind

Har du ikke allerede en bruger? Opret dig her.

FÅ VORES STORE NYTÅRSUDGAVE AF FORMUE

Her er de 10 bedste aktier i 2022

Tilbuddet udløber om:
dage
timer
min.
sek.

Analyse af og prognoser for Fixed Income (statsrenter og realkreditrenter)

Direkte adgang til opdaterede analyser fra toneangivende finanshuse:

Goldman Sachs

Fidelity

Danske Bank

Morgan Stanley

ABN Amro

Jyske Bank

UBS

SEB

Natixis

Handelsbanken

Merril Lynch 

Direkte adgang til realkreditinstitutternes renteprognoser:

Nykredit

Realkredit Danmark

Nordea

Analyse og prognoser for kort rente, samt for centralbankernes politikker

Links:

RBC

Capital Economics

Yardeni – Central Bank Balance Sheet 

Investing.com: FED Watch Monitor Tool

Nordea

Scotiabank